ATE276995T1 - Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren - Google Patents

Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren

Info

Publication number
ATE276995T1
ATE276995T1 AT01924700T AT01924700T ATE276995T1 AT E276995 T1 ATE276995 T1 AT E276995T1 AT 01924700 T AT01924700 T AT 01924700T AT 01924700 T AT01924700 T AT 01924700T AT E276995 T1 ATE276995 T1 AT E276995T1
Authority
AT
Austria
Prior art keywords
estrogen receptor
receptor modulators
selective estrogen
triphenylethylene derivatives
halogenated
Prior art date
Application number
AT01924700T
Other languages
English (en)
Inventor
Robert F Kaltenbach Iii
George L Trainor
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of ATE276995T1 publication Critical patent/ATE276995T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
AT01924700T 2000-04-05 2001-04-05 Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren ATE276995T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19457900P 2000-04-05 2000-04-05
PCT/US2001/011080 WO2001077057A2 (en) 2000-04-05 2001-04-05 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
ATE276995T1 true ATE276995T1 (de) 2004-10-15

Family

ID=22718125

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01924700T ATE276995T1 (de) 2000-04-05 2001-04-05 Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren

Country Status (8)

Country Link
US (1) US6528681B2 (de)
EP (1) EP1268389B1 (de)
JP (1) JP2004517033A (de)
AT (1) ATE276995T1 (de)
AU (1) AU2001251330A1 (de)
CA (1) CA2403144A1 (de)
DE (1) DE60105785D1 (de)
WO (1) WO2001077057A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6180731A (ja) * 1984-09-28 1986-04-24 Toshiba Corp 管球の製造方法
AU2002323098A1 (en) * 2001-08-11 2003-03-03 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
ATE399775T1 (de) 2003-10-08 2008-07-15 Smithkline Beecham Corp Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors
US7196119B2 (en) 2003-10-21 2007-03-27 The Regents Of The University Of California Development of new selective estrogen receptor modulators
WO2009149081A1 (en) * 2008-06-02 2009-12-10 Novelmed Therapeutics, Inc. Method for treating inflammatory conditions
BR112012031464A2 (pt) 2010-06-10 2020-08-04 Aragon Pharmaceuticals, Inc. moduladores do receptor de estrogênio e os seus usos
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) * 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
EA201491530A1 (ru) * 2012-03-20 2015-07-30 Серагон Фармасьютикалс, Инк. Модуляторы рецепторов эстрогенов и их применение
JP2016517420A (ja) 2013-03-14 2016-06-16 セラゴン ファーマシューティカルズ， インク． 多環式エストロゲン受容体モジュレーター及びその使用
WO2016106146A1 (en) 2014-12-23 2016-06-30 The Regents Of The University Of California Methods for immunomodulation of cancer and infectious disease therapy
MX2021009569A (es) 2019-02-12 2021-09-08 Radius Pharmaceuticals Inc Procesos y compuestos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
CZ300929B6 (cs) 1997-08-15 2009-09-16 Duke University Sloucenina pro použití pri lécení nebo prevenci estrogenem stimulované rakoviny

Also Published As

Publication number Publication date
US6528681B2 (en) 2003-03-04
WO2001077057A2 (en) 2001-10-18
EP1268389A2 (de) 2003-01-02
EP1268389B1 (de) 2004-09-22
AU2001251330A1 (en) 2001-10-23
US20020013297A1 (en) 2002-01-31
DE60105785D1 (de) 2004-10-28
CA2403144A1 (en) 2001-10-18
WO2001077057A3 (en) 2002-06-13
JP2004517033A (ja) 2004-06-10

Similar Documents

Publication Publication Date Title
WO2003016270A3 (en) Selective estrogen receptor modulators
DE60105785D1 (de) Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren
DK1353672T3 (da) Syntese af 4-amino-thalidomidenantiomerer
TW200736196A (en) 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
MXPA04003439A (es) Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc.
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
ZA200108285B (en) Antibody compositions and methods for cancer treatment by selectively inhibiting VEGF.
MXPA03004549A (es) Derivados de 3-arilindola y su uso como agonistas del receptor cb2.
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
IL139956A0 (en) Conformationally constrained backbone cyclized somatostatin analogs
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
AU2001231710A1 (en) Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
PT925301E (pt) Derivados altamente lipofilos de camptotecina
SI2206719T1 (sl) Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien
WO2001071022A3 (en) Lpa receptor agonists and antagonists and methods of use
AU2003288644A1 (en) Mercapto-phenyl-naphthyl-methane derivatives and preparation thereof
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
DK1406902T3 (da) Hexahydroazepino[4,5-g]indoler og -indoliner som 5-HT-receptor-ligander
GB0425548D0 (en) Radiolabelled ligands
WO2004089313A3 (en) Novel olanzapine forms and related methods of treatment
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
DE60220179D1 (de) Substituierte benzopyrane als selektive agonisten am östrogenrezeptor-beta
TR200401601T4 (tr) Seçici estrojen reseptörü modülatörleri olarak trifeniletilen türevlerinin özel tuz biçimleri

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties